e-learning
resources
Berlin 2008
Monday, 06.10.2008
Treatment and outcome in hospitalised patients with community-acquired pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of host status, bacteria and antibiotic therapy on systemic inflammatory response syndrome (SIRS) development in community-acquired pneumonia (CAP)
F. Sanz, J. Blanquer, E. Fernández, A. Cervera, C. Aguar, E. Chiner, R. Blanquer (Valencia, Spain)
Source:
Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Session:
Treatment and outcome in hospitalised patients with community-acquired pneumonia
Session type:
E-Communication Session
Number:
1858
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Sanz, J. Blanquer, E. Fernández, A. Cervera, C. Aguar, E. Chiner, R. Blanquer (Valencia, Spain). Impact of host status, bacteria and antibiotic therapy on systemic inflammatory response syndrome (SIRS) development in community-acquired pneumonia (CAP). Eur Respir J 2008; 32: Suppl. 52, 1858
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Effects of empirical antibacterial therapy on the degree of systemic inflammatory response in patients with severe community-acquired pneumonia (SCAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 2s
Year: 2003
Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
Effects of systemic steroids in patients with severe community-acquired pneumonia
Source: Eur Respir J 2007; 30: 951-956
Year: 2007
Differences between local and systemic inflammatory response in patients with community acquired pneumonia (CAP)
Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia
Year: 2011
An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Community-aquired pneumonia: systemic and local inflammatory response in treatment failure
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
Clinical pulmonary infection score (CPIS) and inflammatory response in patients with new pulmonary infiltrates and suspected ventilator acquired pneumonia (VAP)
Source: Annual Congress 2005 - Diagnosis and prognosis of ventilator associated pneumonia: the clinical track
Year: 2005
Evaluation of severity, inflammatory response and adherence to treatment guidelines impact on community-acquired pneumonia outcomes
Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia
Year: 2008
The impact of time on the systemic inflammatory response in pneumococcal pneumonia
Source: Eur Respir J 2010; 35: 614-618
Year: 2010
Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015
Systemic cytokine levels in community-acquired pneumonia and their association with disease severity
Source: Eur Respir J 2002; 20: 990-995
Year: 2002
Systemic cytokine response in patients with community-acquired pneumonia
Source: Eur Respir J 2011; 37: 1431-1438
Year: 2011
Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Influence of antibiotic pre-treatment on inflammatory markers in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
Relevance of correct antibiotic choice in community-acquired pneumonia (CAP)
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005
Is it connection between systemic inflammation and risk of thrombotic disorders (by Padua scale) in hospitalized patients with community-acquired pneumonia (CAP)?
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Respiratory pathogens, immunodeficiency or systemic response – What comes first in the etiology of severe community-acquired pneumonia (sCAP)
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013
Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP)
Source: Eur Respir J 2002; 20: Suppl. 38, 418s
Year: 2002
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept